| |
| Overview |
| The Right to Good Health |
| In our journey of 25 years, our pursuit for excellence has been driven by two major thrusts: a customer-centric attitude and more importantly, an unrelenting commitment to improve the quality of human life. |
|
| Our aim is to not only facilitate the world’s population with unhindered access to excellent medication, but to create a sustainable model that addresses the unmet medical needs of society and improves health and well-being, ultimately raising the overall quality of life. |
|
| However, creating affordability is challenging given the prohibitive costs of drug development. High-priced medicines remain out of the reach of millions of people who need them. Even in high-income countries, branded proprietary drugs are unaffordable for many and particularly for the growing numbers of the uninsured. The problem is amplified in emerging economies, where although expenditure per capita on medicines is relatively low, it is substantial and often unsustainable. |
|
| As a responsible leading global pharmaceutical company we believe it is our duty to: |
|
|
|
|
| This philosophy was the founding premise of Dr. Reddy’s and has been fuelling the organisation’s growth ever since 1984. |
|
| Today, we are vertically integrated - right from the process development of APIs and formulations to the submission of Abbreviated New Drug Applications (ANDAs) and the subsequent manufacturing of finished dosages. We address these tenets either directly or indirectly through our three core businesses. |
|
|
| |
|
| |
|
|
 |
Branded Generics |
|
| |
We seek to build a portfolio that is strongly differentiated and offers compelling advantages to doctors and patients. |
|
|
|
|
|
Unbranded Generics |
|
|
We aim to offer IP and technology -advantaged products and ensure that customers, including pharmacy chains and distributors are ‘first-to-market’ for our products and help establish high product availability combined with low inventories, Leading to higher profitability |
|
|
|
|
|
Vertical integration and process innovation ensure peak performance and enable our products to remain competitive and affordable. |
|
| |
|
|
|
| |
Pharmaceutical Services and Active Ingredients (PSAI) |
|
|
|
| |
|
| |
|
|
|
Active Pharmaceutical Ingredients (API) |
|
| |
Our product offerings are geared to offer intellectual property and technology-advantaged products to enable launches ahead of others at competitive prices. |
|
|
|
|
|
Custom Pharmaceutical Services (CPS) |
|
|
In the area of services, we aim to offer niche product service capabilities, technology platforms, and competitive cost structures to innovator companies to enable them to provide new cures cost efficiently. |
|
| |
|
|
|
|
|
| |
|
| |
|
|
|
Differentiated Formulations |
|
| |
Our emerging Differentiated Formulations portfolio, which consists of new, synergistic combinations as well as technologies that improve safety and/or efficacy by modifying pharmacokinetics of existing medicines, is focused on addressing clinically unmet needs. We are also investigating new indications for existing medicines. |
|
|
|
|
|
New Chemical Entities (NCE) |
|
|
We are focused on the discovery, development and commercialisation of novel small molecule agents in therapeutic areas such as bacterial infections, metabolic disorders, pain, and inflammation. |
|
|
|
|
|
Generic Biopharmaceuticals |
|
|
Patent expiries in the immediate future, present opportunities to serve the global population with high quality, low cost equivalents of proprietary biopharmaceuticals. |
|
|
|
|
|
Our proven product development capabilities coupled with commercial reach will help us position ourselves as a global leader in this industry. |
|
| |
|
|
|
| |
| We continuously strive to add more medicines to our portfolio to inject affordability in a broader spectrum of cures. Towards this objective, we have developed a robust and diversified product pipeline by leveraging on our strengths in science and technology which include synthetic organic chemistry, formulation development, biologics development and small molecule based drug discovery. |
|
| Moreover, our execution excellence frame work comprising Lean Manufacturing Principles and Quality by Design (QbD) further provides us with a solid foundation to create sustainable customer value across all our activities. |
|
| In an effort to increase the reach of our medicines and in turn, broad-base access to their therapeutic benefits we continually explore diversification into newer geographies. We have already established a strong presence both in highly regulated markets such as the United States (US), the United Kingdom and Germany, as well as in emerging markets such as India, Russia and from countries of Soviet Union, Venezuela and Romania. |
|
| We regularly donate our short-dated medicines to the United Nations (UN). The UN has effective channels and mechanisms to initiate and enhance drug intervention where it is needed
the most. |
| |
| |
|
